Crystec Ltd United Kingdom

CrystecPharma is a crystal and particle engineering company applying proprietary modified supercritical fluid (SCF) technologies to improve the performance of medicines. Our technology enables drug molecules to be crystallised in new forms and novel particles to be manufactured in ways that greatly enhance their therapeutic performance. Crystec has an enabling platform which can be applied to small and large molecules, to optimise a range of medicine dosage forms (e.g. oral, inhaled, intranasal, subcutaneous, sublingual).

Crystec works with the global pharmaceutical and health care industry to solve drug particle formation, formulation and process challenges. We are also developing our own innovative therapies in important areas of unmet clinical need, including women’s health, urology and treating respiratory disease. Crystec’s proprietary ‘mSAS’ (modified Supercritical Anti-Solvent) drug delivery technology is enabled by a highly efficient, stable and fully scalable manufacturing process and is approved by regulatory authorities. The mSAS platform creates unique opportunities to improve medicines in ways that can transform the quality of life for many patients.


Organisation type
Paul Thorning
Catherine Hunter
Business Development Director 


GTN - Transforming drug discovery through interdisciplinary innovation. At GTN, a multidisciplinary, innovation-driven company, we are searching the astronomically large space of drug-like molecules with our unique patented technology, Generative Tensorial Networks. Our software combines and builds upon techniques from machine learning and quantum physics to simulate, filter and search for molecules, discovering molecules entirely hidden from view. This will create substantial efficiencies in the whole drug development cycle.

Noor Shaker

High Force Research United Kingdom

Headquartered in Durham, UK, High Force Research are proud to remain a truly independent chemistry CRO and R&D partner. We have core expertise in chemical R&D, process optimisation & development, custom synthesis, scale-up and cGMP manufacture of small molecule API's and their intermediates for pre-clinical studies and Phase I/II clinical trials. We collaborate with discovery groups, start-ups and spin-offs from academia and industry in synthesising new materials for proof-of-concept studies and in process development on the route to market. High Force Research has established dual contribution, shared risk joint venture collaborations with universities and SME's. We invest expertise, time and facilities to jointly develop novel, small molecule NCE's and clinical candidates. 
Jennifer Wallis
Business Development Executive 

IAG United Kingdom

IA-Group is a strategic partner to bio-pharmacutical companies. We bring extensive therapeutic knowledge and regulatory expertise in strategic use of clinical imaging to enhance understanding of the mode of action, to increase the efficiency of clinical decisions and to accelerate drug development.

IA’s operations team leverage our global footprint and the next-generation cloud based proprietry platform Dynamika to de-risk trial execution and to ensure data quality and integrity. Our venture arm pioneer unique targeted investment and risk-sharing models to enable our clients to reach the next value inflection point faster. We fuse decades of theraputic insight and agile culture to meet today's speed and high standard of therapeutic innovation.


Organisation type
Diana Roettger
Head of Scientific and Medical Affairs 


Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood test to transform the care of cancer patients. The Company’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge and backed by multiple high calibre publications. Its lead product, InVisionFirst™-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for NSCLC patients. Inivata is partnering with pharmaceutical and biotechnology companies on InVisionFirst™-Lung and its wider platform, which is applicable to a range of cancer types. The Company has a CLIA laboratory in Research Triangle Park, NC and laboratories in Cambridge, UK. For more information, please go to Follow us on Twitter @Inivata.

Organisation type
Thomas Schlumpberger
VP Business Development 

Intract Pharma United Kingdom

Intract Pharma Limited is an oral drug delivery licensing and product development company offering a range of proprietary formulation technologies to deliver novel and optimised therapeutics targeted to patient needs. The company is a spin-out of University College London, and is centred around over 15 years of research and innovation from the laboratory of Professor Abdul Basit. Intract's range of formulation technologies includes Phloral™ for colon targeted delivery, and ProRelease™, a versatile microparticulate delivery system. ntract Pharma is a licensing and product development company offering state-of-the-art formulation technologies and specialist gastrointestinal models to develop advanced new therapeutics

Organisation type
Bill lindsay

Invest Liverpool

Liverpool Vision is the city’s economic development company which integrates economic development and business and enterprise support designed to accelerate the city’s growth and build a sustainable economy. We have played a pivotal role in co-ordinating the delivery of the city’s economic and physical renaissance over the last decade, working within the strategic leadership of the City Council and the Mayor of Liverpool.

Mr Matt Biagetti
Investment Manager 

Karma Oncology Ltd United Kingdom

Karma Oncology, Ltd is a unique company which specializes in preparing tailored clinical development plans, clinical trial design and execution (everything from preparing the protocol through site selection, regulatory/ethics submissions, monitoring, project management, reporting and final study report writing). Of note, Karma Oncology successfully designed and executed an adaptive clinical trial with an autologous cell therapy product in Europe & North America and has designed and executed several CAR-T trials.

Headquartered in Scotland, the team of experts is based across Europe & North America, and experience encompasses solid tumours and haematological malignancies in a wide range of therapeutic approaches.

Organisation type
Karen Williams

Life Sciences in the Northern Powerhouse (Bionow) United Kingdom

Organisation type
Miss Diane Quinn
Events Manager 

LSX Ltd United Kingdom

LSX is the world’s first invoice exchange built on the blockchain. Invoices bought from alternative finance marketplaces around the world will be traded on this secondary exchange. LSX allows trading in fiat and cryptocurrency, including bitcoins and ethers, and is due for public release in late 2018.

Organisation type
Matthew Pullan
Senior Vice President